Keywords: biogen, genentech, xoma, square, up, biologicals, psoriasis

Biogen, Genentech and Xoma square up with biologicals for psoriasis

Article | 25 June 2001

Print This

Genentech and Xoma presented preliminary results on June 22 from thefirst of two pivotal Phase III trials of Xanelim (efalizumab), the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in